SLC5A2 and pneumonia: SGLT2 inhibitors significantly reduced the risk of COPD, pneumonia, respiratory failure, and bronchitis in both groups, with similar odds ratios and confidence intervals, suggesting consistent protective effects irrespective of T2D status.